Epidemiological data from Mayo Clinic reveal that ILD development in RA patients has a hazard ratio (HR) of 8.96 which is further heightened in patients with increased age, male gender, smokers and with high disease burden (high ESR, HAQ, RF and ACPA titers).1 Preliminary data from the “Attikon” University Hospital RA-ILD cohort show that 31% of the patients are male, 56% are seropositive for RF and/or ACPA, and 44% have radiographic erosions. This evidence concerns the gene PRTN3 and interstitial lung disease.